Impact of Age-3 Urine Screening on Diagnosis and Treatment Timing in Alport Syndrome
Our study showed that approximately 30% of patients with Alport syndrome had the opportunity to be diagnosed through age-3 urine screening, and among them, more than half were already eligible for RAS-I treatment. Urine screening may be an optimal method for contributing to a delay in the progression to ESKD in patients with Alport syndrome.
Authors
- Hideaki Kitakado (ORCID: https://orcid.org/0000-0001-7763-4675)
- Kandai Nozu (ORCID: https://orcid.org/0000-0002-0290-3137)
- China Nagano (ORCID: https://orcid.org/0000-0003-4946-1345)
- Tomohiko Yamamura (ORCID: https://orcid.org/0000-0001-6107-1169)
- Chika Ueda (ORCID: https://orcid.org/0000-0003-3390-0235)
- Yu Tanaka (ORCID: https://orcid.org/0000-0001-5107-2491)
- Yuta Inoki (ORCID: https://orcid.org/0009-0005-8645-5464)
- Shuhei Aoyama
- Yuka Kimura (ORCID: https://orcid.org/0000-0001-9072-9329)
- Nana Sakakibara
- Shingo Ishimori (ORCID: https://orcid.org/0000-0003-3863-2743)
- Tomoko Horinouchi (ORCID: https://orcid.org/0000-0003-1655-6030)
Institutions
- Kobe University (JP)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1016/j.ekir.2025.09.022
- Citations
- 1
- Primary Topic
- Cell Adhesion Molecules Research
- Type
- article
- Field-Weighted Citation Impact
- 1.62
Funders
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science